Access legacy protocols, associated case reports and data for your research project.
The ACRIN® legacy protocols and associated case report forms are available below as a reference and for data access requests for ancillary research projects.
Researchers interested in accessing data from the ACRIN legacy trials should submit requests via the ECOG-ACRIN Data Access Committee.
MR Imaging and MR Spectroscopic Imaging of Prostate Cancer Prior to Radical Prostatectomy: A Prospective Multi-Institutional Clinicopathological Study
The National CT Colonography Trial
Phase II Trial of Neoadjuvant/Adjuvant STI-571 (Gleevec NSC 716051) for Primary and Recurrent Operable Malignant Gastrointestinal Stromal Tumors Expressing the KIT Receptor Tyrosine Kinase (CD117)
Multicenter Feasibility Study of Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma in Cirrhotic Patients
A Phase 2, Multicenter Evaluation of 18F-Fluoride PET as a Pharmacodynamic Biomarker for Dasatinib, a Src Kinase Inhibitor, in Men With Castration-Resistant Prostate Cancer and Bone Metastases (BMS #180-279)
A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation
Digital Versus Film-Screen Mammography (DMIST)
Contrast-Enhanced Breast MRI for Evaluation of Patients Undergoing Neoadjuvant Treatment for Locally Advanced Breast Cancer
Screening Breast Ultrasound in High-Risk Women
MRI Evaluation of the Contralateral Breast in Women With a Recent Diagnosis of Breast Cancer
Phase II Study of 3'-Deoxy-3'-18F Fluorothymidine (FLT) in Invasive Breast Cancer
Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging (DOSI)
Diffusion Weighted MR Imaging Biomarkers for Assessment of Breast Cancer Response to Neoadjuvant Treatment: A sub-study of the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis)
A Multi-Center Study Evaluating the Utility of Diffusion Weighted Imaging for Detection and Diagnosis of Breast Cancer
Role of Radiology in the Pretreatment Evaluation of Invasive Cervical Cancer
Utility of Preoperative FDG-PET/CT Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA =4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 or 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage)
Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer
Prognostic Perfusion CT in Gynecological Cancer: A Randomized Phase III Trial of Every-3-Weeks Paclitaxel versus Dose Dense Weekly Paclitaxel in Combination with Carboplatin With or Without Concurrent and Consolidation Bevacizumab in the Treatment of Primary Stage I, II, III, or IV Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer
Staging With MR Perfusion Imaging and MR Spectroscopy. ACRIN 6677 is conducted in collaboration with RTOG 0625: A Randomized Trial of Bevacizumab With Temozlomide in Recurrent Glioblastoma
Multicenter, Phase II Assessment of Tumor Hypoxia in Glioblastoma Using 18F-Fluoromisonidazole (FMISO) With PET and MRI
A Multicenter Trial of FDG-PET/CT Staging of Head and Neck Cancer and Iits Impact on the N0 Neck Surgical Treatment in Head and Neck Cancer Patients
Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Contemporary Screening for the Detection of Lung Cancer
Positron Emission Tomography Pre- and Post-treatment Assessment for Locally Advanced Non-small Cell Lung Carcinoma
FDG-PET/CT as a Predictive Marker of Tumor Response and Patient Outcome: Prospective Validation in Non-small Cell Lung Cancer
Randomized Phase 2 Trial of Individualized Adaptive Radiotherapy Using During-treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-small Cell Lung Cancer (NSCLC)
